» Articles » PMID: 33082517

Photoreceptor Protection by Mesenchymal Stem Cell Transplantation Identifies Exosomal MiR-21 As a Therapeutic for Retinal Degeneration

Overview
Specialty Cell Biology
Date 2020 Oct 21
PMID 33082517
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Photoreceptor apoptosis is recognized as one key pathogenesis of retinal degeneration, the counteraction of which represents a promising approach to safeguard visual function. Recently, mesenchymal stem cell transplantation (MSCT) has demonstrated immense potential to treat ocular disorders, in which extracellular vesicles (EVs), particularly exosomes, have emerged as effective ophthalmological therapeutics. However, whether and how MSCT protects photoreceptors against apoptotic injuries remains largely unknown. Here, we discovered that intravitreal MSCT counteracted photoreceptor apoptosis and alleviated retinal morphological and functional degeneration in a mouse model of photoreceptor loss induced by N-methyl-N-nitrosourea (MNU). Interestingly, effects of MSCT were inhibited after blockade of exosomal generation by GW4869 preconditioning. Furthermore, MSC-derived exosomal transplantation (EXOT) effectively suppressed MNU-provoked photoreceptor injury. Notably, therapeutic efficacy of MSCT and EXOT on MNU-induced retinal degeneration was long-lasting as photoreceptor preservance and retinal maintenance were detected even after 1-2 months post to injection for only once. More importantly, using a natural occurring retinal degeneration model caused by a nonsense mutation of Phosphodiesterase 6b gene (Pde6b), we confirmed that MSCT and EXOT prevented photoreceptor loss and protected long-term retinal function. In deciphering therapeutic mechanisms regarding potential exosome-mediated communications, we identified that miR-21 critically maintained photoreceptor viability against MNU injury by targeting programmed cell death 4 (Pdcd4) and was transferred from MSC-derived exosomes in vivo for functional regulation. Moreover, miR-21 deficiency aggravated MNU-driven retinal injury and was restrained by EXOT. Further experiments revealed that miR-21 mediated therapeutic effects of EXOT on MNU-induced photoreceptor apoptosis and retinal dysfunction. These findings uncovered the efficacy and mechanism of MSCT-based photoreceptor protection, indicating exosomal miR-21 as a therapeutic for retinal degeneration.

Citing Articles

Mesenchymal stem cells and mesenchymal stem cell-derived exosomes: a promising strategy for treating retinal degenerative diseases.

An W, Zhang W, Qi J, Xu W, Long Y, Qin H Mol Med. 2025; 31(1):75.

PMID: 39984849 PMC: 11846226. DOI: 10.1186/s10020-025-01120-w.


Identification of glutamine as a potential therapeutic target in dry eye disease.

Chen X, Zhang C, Peng F, Wu L, Zhuo D, Wang L Signal Transduct Target Ther. 2025; 10(1):27.

PMID: 39837870 PMC: 11751114. DOI: 10.1038/s41392-024-02119-1.


Exosomes derived from IFNγ-stimulated mesenchymal stem cells protect photoreceptors in RCS rats by restoring immune homeostasis through tsRNAs.

A L, Qu L, He J, Ge L, Gao H, Huang X Cell Commun Signal. 2024; 22(1):543.

PMID: 39538308 PMC: 11562488. DOI: 10.1186/s12964-024-01920-3.


Contribution of PKS+ to colon carcinogenesis through the inhibition of exosomal miR-885-5p.

He X, Ren E, Dong L, Yuan P, Zhu J, Liu D Heliyon. 2024; 10(18):e37346.

PMID: 39315148 PMC: 11417213. DOI: 10.1016/j.heliyon.2024.e37346.


Photoreceptor-targeted extracellular vesicles-mediated delivery of Cul7 siRNA for retinal degeneration therapy.

Guo D, Sun Y, Wu J, Ding L, Jiang Y, Xue Y Theranostics. 2024; 14(13):4916-4932.

PMID: 39267786 PMC: 11388070. DOI: 10.7150/thno.99484.


References
1.
Murakami Y, Notomi S, Hisatomi T, Nakazawa T, Ishibashi T, Miller J . Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog Retin Eye Res. 2013; 37:114-40. PMC: 3871865. DOI: 10.1016/j.preteyeres.2013.08.001. View

2.
Marigo V . Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. Cell Cycle. 2007; 6(6):652-5. DOI: 10.4161/cc.6.6.4029. View

3.
Verbakel S, van Huet R, Boon C, den Hollander A, Collin R, Klaver C . Non-syndromic retinitis pigmentosa. Prog Retin Eye Res. 2018; 66:157-186. DOI: 10.1016/j.preteyeres.2018.03.005. View

4.
Park S, Moisseiev E, Bauer G, Anderson J, Grant M, Zam A . Advances in bone marrow stem cell therapy for retinal dysfunction. Prog Retin Eye Res. 2016; 56:148-165. PMC: 5237620. DOI: 10.1016/j.preteyeres.2016.10.002. View

5.
Zakirova E, Valeeva A, Aimaletdinov A, Nefedovskaya L, Akhmetshin R, Rutland C . Potential therapeutic application of mesenchymal stem cells in ophthalmology. Exp Eye Res. 2019; 189:107863. DOI: 10.1016/j.exer.2019.107863. View